eFFECTOR Therapeutics Income Statement

Financials in millions USD. Fiscal year is January - December.

Millions USD. Fiscal year is Jan - Dec.

Year Ending	TTM	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020	Dec 31, 2019
Revenue	0.16	0	3.55	1.43	42	0
Revenue Growth (YoY)	-95.44%	-	148.46%	-96.60%	-	-
Cost of Revenue	0.11	0.11	0.05	0.02	21.83	0.31
Gross Profit	0.05	-0.11	3.5	1.41	20.17	-0.31
Selling, General & Admin	11.09	10.93	12.64	13.37	4.35	4.72
Research & Development	21.56	22.81	23.31	19.96	21.83	23.58
Other Operating Expenses	-0.02	0	-3.55	-1.43	0.01	0
Operating Expenses	32.65	33.73	32.4	31.9	26.18	28.3
Operating Income	-33.15	-33.84	-32.4	-31.9	15.82	-28.61
Interest Income	1.07	0.97	0.44	0.01	0.07	0.24
Interest Expense	1.48	-2.92	2.25	1.76	1.33	1.38
Other Expense / Income	1.07	5.86	-11.55	-49.43	-0.01	-0.01
Pretax Income	-34.63	-35.81	-22.67	15.8	14.56	-29.74
Income Tax	0	0	-9.74	-0.02	0.35	0
Net Income	-34.63	-35.81	-12.93	15.8	14.21	-29.74
Net Income Growth	-	-	-	11.17%	-	-
Shares Outstanding (Basic)	4	2	2	2	1	1
Shares Outstanding (Diluted)	4	2	2	2	1	1
Shares Change	142.94%	32.77%	1.96%	169.91%	8.35%	-
EPS (Basic)	-13.31	-16.37	-7.85	9.78	23.74	-53.83
EPS (Diluted)	-13.31	-16.37	-7.85	9.78	23.74	-53.83
EPS Growth	-	-	-	-58.80%	-	-
Free Cash Flow	-29.28	-29.65	-26.09	-24.93	13.68	-27.6
Free Cash Flow Per Share	-7.17	-13.56	-15.84	-15.43	22.86	-49.96
Gross Margin	31.48%	-	98.51%	98.32%	48.02%	-
Operating Margin	-20463.58%	-	-911.99%	-2230.56%	37.66%	-
Profit Margin	-21376.54%	-	-363.83%	1104.76%	33.84%	-
Free Cash Flow Margin	-18070.99%	-	-734.34%	-1743.36%	32.57%	-
Effective Tax Rate	-	-	-	-0.15%	2.41%	-
EBITDA	-32.85	-33.73	-32.4	-31.9	16.06	-28.3
EBITDA Margin	-20279.63%	-	-911.99%	-2230.56%	38.23%	-
Depreciation & Amortization	0.11	0.11	0.05	0.02	0.16	0.31
EBIT	-32.96	-33.84	-32.46	-31.92	15.9	-28.61
EBIT Margin	-20348.15%	-	-913.48%	-2232.24%	37.85%	-

Sources: The data provider is Financial Modeling Prep and the numbers are sourced from SEC filings.